Delivery Order SPE2DB22D3501-SPE2DB25FXK27
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Dupixent 300 mg/2 ml pen injections (2 ml quantity) with a ceiling value of $21,486.82. This is a firm fixed price delivery order issued under a non-competitive, non-set-aside procurement. The order is set for ultimate completion by September 11, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,709.46 for Dupixent 300 mg/2 ml pen injections on August 19, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply relationship with DLA. The place of performance is listed as Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order falls under AmerisourceBergen's comprehensive...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $27,256.30 on August 7, 2025, for the supply of Dupixent 300 mg/2 mL pen injections. The contract represents a firm fixed-price delivery order with an ultimate completion date of August 8, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. This award was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $11,758.26. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 8, 2025. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various inflammatory conditions,...
- The Defense Logistics Agency awarded a $63,152.32 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 4, 2025, with completion expected by August 5, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $91,743.02 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on September 2, 2025, with an ultimate completion date of September 3, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $12,957.54 under firm fixed price terms. The delivery order, which represents a child contract under a larger vehicle, has an ultimate completion date of August 25, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This award was made through competitive procedures...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $6,612.18. This is a firm fixed price delivery order with no set-aside designation, issued competitively, and is scheduled for completion by September 10, 2025. The order will be fulfilled from the vendor's location in Conshohocken, Pennsylvania, where AmerisourceBergen's corporate headquarters is based. This...
- The Defense Logistics Agency awarded a $48,351.90 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 30, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $68,378.40. This firm fixed-price delivery order is not set-aside and represents a competitive award to the prime contractor, with an ultimate completion date of September 18, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXK27Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Dupixent 300 mg/2 mL pen injections with a contract ceiling value of $32,619.13. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 18, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis, making it a critical pharmaceutical supply for military beneficiaries requiring specialty immunology treatment. AmerisourceBergen's extensive federal contract portfolio with the Defense Logistics Agency demonstrates its capability to fulfill complex pharmaceutical procurement requirements across multiple therapeutic domains, supporting the Defense Health Agency and broader Department of Defense healthcare systems. The firm fixed-price structure and competitively awarded nature of this delivery order reflect AmerisourceBergen's established role as a primary pharmaceutical distributor within the federal medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $32.6k | 9/17/25 |